85PEvaluation of the safety and the tolerability of durvalumab plus tremelimumab combined with FOLFOX in metastatic colorectal cancer (MEDITREME). (17th December 2018) - Fumet, J-D; Isambert, N; Hervieu, A; Zanetta, S; Guion, J-F; Hennequin, A; Rederstorff, E; Bertaut, A; Ghiringhelli, F